38 reports of this reaction
1.3% of all BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B reports
#19 most reported adverse reaction
PRODUCT QUALITY ISSUE is the #19 most commonly reported adverse reaction for BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B, manufactured by H E B. There are 38 FDA adverse event reports linking BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B to PRODUCT QUALITY ISSUE. This represents approximately 1.3% of all 2,903 adverse event reports for this drug.
Patients taking BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B who experience product quality issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT QUALITY ISSUE is a less commonly reported adverse event for BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B, but still significant enough to appear in the safety profile.
In addition to product quality issue, the following adverse reactions have been reported for BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B:
The following drugs have also been linked to product quality issue in FDA adverse event reports:
PRODUCT QUALITY ISSUE has been reported as an adverse event in 38 FDA reports for BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT QUALITY ISSUE accounts for approximately 1.3% of all adverse event reports for BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B, making it a notable side effect.
If you experience product quality issue while taking BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.